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“CCN” is an acronym referring to the first letter of each of the first three members of this original group of mammalian
functionally and phylogenetically distinct extracellular matrix (ECM) proteins [i.e., cysteine-rich 61 (CYR61), connective
tissue growth factor (CTGF), and nephroblastoma-overexpressed (NOV)]. Although “CCN” genes are unlikely to have
arisen from a common ancestral gene, their encoded proteins share multimodular structures in which most cysteine
residues are strictly conserved in their positions within several structural motifs. The CCN genes can be subdivided into
members developmentally indispensable for embryonic viability (e.g., CCN1, 2 and 5), each assuming unique
tissue-specific functions, and members not essential for embryonic development (e.g., CCN3, 4 and 6), probably due to
a balance of functional redundancy and specialization during evolution. The temporo-spatial regulation of the CCN
genes and the structural information contained within the sequences of their encoded proteins reflect diversity in their
context and tissue-specific functions. Genetic association studies and experimental anomalies, replicated in various
animal models, have shown that altered CCN gene structure or expression is associated with “injury” stimuli—whether
mechanical (e.g., trauma, shear stress) or chemical (e.g., ischemia, hyperglycemia, hyperlipidemia, inflammation).
Consequently, increased organ-specific susceptibility to structural damages ensues. These data underscore the critical
functions of CCN proteins in the dynamics of tissue repair and regeneration and in the compensatory responses
preceding organ failure. A better understanding of the regulation and mode of action of each CCN member will be
useful in developing specific gain- or loss-of-function strategies for therapeutic purposes.Introduction
The CCN proteins belong to a group of extracellular
matrix (ECM)-associated proteins exhibiting a regulatory
rather than structural role in the extracellular environ-
ment. As such, these molecules have been classified as
members of the matricellular protein family which also
includes thrombospondins 1 and 2, osteopontin, tenas-
cins C and X, and the SPARC (secreted protein acidic
and rich in cysteine)-related proteins, SC1 (SPARCL1)
and QR1 [1]. Overall, matricellular proteins are com-
posed of modular motifs found in other ECM proteins.* Correspondence: bchaqour@downstate.edu
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such as fibronectin, laminins, and fibrillar collagens, all
of which contribute to the structural stability and scaf-
folding of the tissues [2]. All CCN proteins are expressed
in a variety of organisms, and their expression is spatially
and temporally regulated during development. In adults,
the CCN genes are differentially regulated in tissues that
undergo consistent turnover or at sites of injury, repair,
and disease [3]. The encoded CCN proteins regulate cell
migration, proliferation, cell lineage commitment and
tissue specification, morphogenesis, and/or angiogenesis.
Several CCN genes are required for embryonic viability
although each assumes distinct functions in different tis-
sues and cell types. Matricellular proteins other than
CCNs perform similar functions and are co-expressed
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homozygous-null mutations in the thrombospondin 1
(Thbs1), secreted phosphoprotein 1 (Spp1), and tenascin
C (Tnc) genes are born with no obvious abnormalities,
and only some minor anatomical defects (e.g., kinked
tail) emerged during postnatal development. Such an
anatomical abnormality might be the result of a defect
in collagen fibrillogenesis, which is disordered in the
Thbs2-null and Sparc-null mice [5]. Interestingly, the
CCN proteins do not play a role in ECM protein
organization even though they assume other essential
functions in cardiovascular and skeletal development
and pathology. Here, we review the key structural and
functional attributes of each of the CCN molecules and
their relevance in development and diseases.
CCN nomenclature
Although the acronym “CCN” refers to the initials of the
first three members of this group of genes [i.e., cysteine-
rich 61 (CYR61), connective tissue growth factor
(CTGF), and nephroblastoma overexpressed (NOV)],
there are three additional related members named Wnt-
inducible secreted proteins WISP1, WISP2, and WISP3
based on their induction by Wnt ligands. The acronym
CCN followed by a number reflecting the chronology of
the discovery of these proteins, as shown in Table 1, has
been proposed to unify the disparate names used in pub-
lications for this group of proteins and genes in different
species [6]. For instance, CCN1 was referred to as Cyr61
in mouse [7], GIG1 in humans, and CEF10 in chicken
[8], CTGF was referred to as Nov2 in human and fisp12
[9] in mouse, and WISP1 and 2 were sometimes referred
to as ELM1 [10] and COP1 [11], respectively. An at-
tempt by Baxter and Twigg to reclassify these proteins
as insulin-like growth factor binding proteins (IGFBPs)
was not followed as this classification had neither a
functional nor structural basis [12]. Indeed, these pro-
teins have no real IGF binding properties and the affinity
of some of them to IGF is 1000-fold poorer than the ori-




CCN1 CYR61 Cysteine-rich, angiogenic inducer, 61
CCN2 CTGF Connective tissue growth factor
CCN3 NOV Nephroblastoma overexpressed
CCN4 WISP1 WNT1 inducible signaling pathway p
CCN5 WISP2 WNT1 inducible signaling pathway p
CCN6 WISP3 WNT1 inducible signaling pathway p
Murine loci are expressed in centimorgans (CM)appellations such as IGFBP-related proteins (IGFBP-rP)
was not deemed appropriate. A phylogenetic analysis by
Vilmos et al. further supported the concept that the
CCN and IGFBP proteins are separate sets of genes [14].
The unified CCN nomenclature, which has been
endorsed by the International CCN Society (http://
www.ccnsociety.com), emphasizes the structural related-
ness of these molecules and also eliminates any con-
fusion from the multiple names that have previously
been given to them. However, note that the root
symbol CCN is already in use and approved by the
HUGO Gene Nomenclature Committee (HGNC) for
the cyclin gene family, and the original gene symbols
(CYR61, CTGF, NOV, WISP1/2/3) as listed in Table 1
and at the HGNC’s “CYR61/CTGF/NOV matricellular
proteins” webpage (http://www.genenames.org/cgi-bin/
genefamilies/set/1046) are still widely used by many
investigators. While the CCN nomenclature is in-
creasingly adopted and accepted in the literature, and
will be used hereafter in the present review, the ap-
proved gene symbols will be used when a specific
gene is explicitly discussed.
Interestingly, the CCN genes can further be subdivided
into members that are indispensable for embryonic via-
bility (i.e., CCN1, CCN2, and CCN5), and other mem-
bers that are not critical for embryonic development
(i.e., CCN3, 4 and 6) as deficiency in mice of these pro-
teins did not compromise fetal development and re-
sulted in a superficially mild or no phenotype [15–17].
Nevertheless, the classification of the CCN proteins as
matricellular proteins has held up well, since published
data so far continue to lend credence to their matricellu-
lar membership and classification. Of note, the matricel-
lular proteins—not included in the CCN family—now
include other proteins such as periostin, R-spondins,
and the short fibulins including hemicentin, galectins,
small leucine-rich proteoglycans, and autotaxin [4].
These proteins are also structurally and functionally di-
verse, and none of them recapitulate the biological func-






1 1p22.3 3 70.18 cM
6 6q23.2 10 11.84 cM
8 8q24.12 15 21.49 cM
rotein1 8 8q24.22 15 29.3 cM
rotein 2 20 20q13.12 2 84.49 cM
rotein 3 6 6q21 10 20.19 cM
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The primary structure of the CCN genes contains a
common intron-exon pattern with most of the family
members containing five exons interspersed by four in-
trons (Fig. 1). The gene structure can be further divided
into the N-terminus encoded by the first, second, and
third exons and the C-terminus encoded by the fourth
and fifth exons. The N- and C-termini are separated by
a variable hinge region that is sensitive to proteolysis.
The first exon corresponds to the signal peptide se-
quence, followed by four exons that correspond to the
four conserved domains with sequence homologies to
insulin-like growth factor binding proteins (IGFBPs),
von Willebrand factor type C repeat (vWC), thrombos-
pondin type 1 repeat (TSP-1), and a carboxyl domain
(CT) that contains a cysteine knot motif [18, 19] present
in growth factors including transforming growth factor βFig. 1 CCN gene and protein organization. Schematic diagrams of the overal
signal and the homologous domains (IGFBP insulin-like growth factor binding
type 1 repeat, CT carboxy-terminal domain). The specific modular organization(TGFB1), nerve growth factor (NGF), platelet-derived
growth factor (PDGFA), and human chorionic gonado-
tropin [20]. The CT domain is believed to be involved in
dimerization and heparin binding [14]. The exception to
this shared gene structure is CCN5/WISP2, which lacks
the last exon encoding the fourth CT module and con-
tains only four exons.
According to Vilmos et al., CCN genes emerged after
the divergence of vertebrates and invertebrates [14] and
have been characterized from human, mouse, rat, pig,
cow, chicken, quail, and frog (Fig. 2). Zebrafish, which is
partially tetraploid teleost and possesses orthologous pairs
of genes that are found as single copies in mammals, ex-
presses nine genes that have strong homology to the
mammalian CCNs; three are paralogs of CCN1, two of
CCN2, two of CCN4, one of CCN5, and one of CCN6
[21]. No paralog of CCN3 was found. Their tetra-modularl gene (a) and protein domain organization (b) showing the secretory
protein, VWC von Willebrand factor type C repeat, TSP-1 thrombospondin
of each member of this group of genes is shown in c. Not to scale
Fig. 2 Dendrogram showing the phylogenetic relations between the genes encoding the CCN proteins. The total number of differences
between sequences (i.e., probability of relatedness) is shown to the right. The human genes are framed in the diagram. m mus musculus-mouse,
r rattus norvegicus-rat, g gallus gallus-chicken, b bos taurus-cow, s sus scrofa-pig, c canis lupus familiaris-dog, d danio rerio-zebrafish
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other regulatory proteins suggest that the CCN genes are
products of exon shuffling during evolution when multi-
cellular organisms were formed. In this evolutionary
process, other recombination mechanisms have also oc-
curred including DNA duplication, deletion, inversion,
conversion, and translocation [22]. The evolutionary exon
shuffling generated multimodular molecules with four
conserved domains and disulfide linkage patterns [23].
The encoded CCN proteins share about 40–60 %
similarity in their amino acid sequences including aseries of 38 cysteine residues that are strictly con-
served in their position and number and form 17 di-
sulfide bonds spread throughout the entire primary
sequence of these molecules [19] (Fig. 3). The excep-
tions are CCN5, which contains only 28 conserved
cysteines, and CCN6, which lacks 4 cysteines in the
second module [24]. The recombinant remodeling
allowed the four domains of each CCN protein to
fold into unique three-dimensional structures dictated
by the different electrostatic charges on their surfaces.
The latter defined their 3D conformation, their
Fig. 3 Sequence alignments of the CCN proteins. Human sequence alignment was performed using the ClustalW2 multiple sequence alignment
program. The sections of the sequences corresponding to each domain are highlighted using a different color. CCN proteins share 38 conserved
cysteine residues (in red). The exceptions are CCN5 and CCN6, which contain 28 and 34 cysteine residues, respectively
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Interestingly, the relatively long linker region between
the vWC and TSP1 domains and the shorter linkers
between IGFBP and vWC and between TSP1 and CT
provide both an overall flexibility of the full-length
molecule and a local rigidity within the molecule,
with the IGFBP and CT domains (at the extreme N-and C-terminal ends, respectively) cocked in almost
opposite directions. As shown in recent studies of
CCN1, proteolytic cleavage of the protein produces
truncated forms of the molecule in which amino acid
residues hidden in the compact structure of the intact
protein become exposed and readily accessible to re-
ceptors and interacting partners [25].
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CCN1/CYR61
The human CYR61 gene encoding CCN1 was mapped
to chromosome 1 at band p22.3 (Table 1) [26, 27].
Genetic studies have suggested a relationship between
a missense mutation of the CYR61 gene and patients
with severe atrial septal defects [16, 28]. The muta-
tion leads to an exchange of residues with different
properties in a highly conserved position in the N-
terminal IGFBP module of CCN1. Consistent with
these observations, conventional deletion of the Cyr61
gene in mice caused severe atrioventricular septal de-
fects (AVSD) [16]. AVSDs are characterized by the
complete or partial absence of partitioning of the
atrioventricular valve (AV) and are common genetic
disorders that cause congenital heart disease in
humans. CCN1-deficient mice are characterized by
early onset of apoptosis in the AV cushion that likely
hampers successful fusion between the cushion tissue
and the atrial septum. Thus, CYR61 gene sequence
screening may be important in genetic analyses of pa-
tients with congenital heart diseases.
During embryonic development, CCN1 is widely
expressed in the cardiovascular system [9]. Prominent
cardiac expression of CCN1 was seen as early as E8.5 in
mice expressing lacZ under the control of the endogen-
ous Cyr61 promoter. CCN1 expression continued at
E10.5 especially in the trunk arteriosus, which later di-
vides to form the aorta and pulmonary trunks [16].
CCN1 expression was also found in all major arteries
branching from the heart of the developing fetal circula-
tory system. These include the aortic and pulmonary
trunks which are branches of the aortic arches and the
dorsal aorta and the umbilical artery which are of meso-
dermal origin. The generation of CCN1-deficient mice
provided some insights into the vital role of CCN1 dur-
ing cardiovascular development. A large majority of
CCN1 null embryos died of hemorrhage and/or placen-
tal defects between E11.5 and E14.5, while a fraction of
the embryos died earlier as a result of defects in chorio-
allantoic fusion [29]. Vascular defects seemed to origin-
ate either at the chorioallantoic junction, where the
allantois failed to fuse with the placenta resulting in se-
vere undervascularization in the placental labyrinth, or
from defects of large vessel bifurcation resulting in a
poor vascular coverage of the chorionic plate. Large fetal
vessels such as the aorta appeared dilated, similar to
large aneurysms. Vascular cells such as endothelial and
smooth muscle cells were not confined within their
layers and were mislocalized in the media layer of the
aorta. Similarly, endothelial-specific deletion of Cyr61 in
mice resulted in the formation of vessels with a large
diameter and loss of vessel organization into the arteries,
capillaries, and veins [30]. Subsequently, CCN1-deficientembryos suffered from compromised integrity and
hemorrhage of arterial vessels and capillaries.
A Cyr61 promoter-driven reporter gene expressed in
transgenic mice further detected Cyr61 gene expression
in a wide range of other tissues including the respiratory
system, the embryonic skeletal system including the
notochord, sclerotomes, limbs, and developing bone, the
developing nervous system including the ventral spinal
cord, dorsal root ganglia, parts of the mesencephalon
and telencephalon, and the olfactory bulb, the embryonic
epidermis, and the inner root sheath of hair follicles [7].
The tissue-specific function of CCN1 during embryonic
development has not been established although several
laboratories including ours are currently using the Cre-
lox system in mice to determine the functional relevance
of CCN1 expression in different tissues and cells [30]. At
the molecular level, the CCN1 protein seems to act as
an adaptor or scaffold that can bring cytokines and
growth factors into close proximity to the cell surface by
binding integrins, heparan sulfate proteoglycans, and
receptor tyrosine kinases [31–33]. Together with the
known adhesive and chemotactic functions of the re-
combinant protein, CCN1 may promote cell migration
and guidance during tissue patterning and differenti-
ation. The CCN1-integrin interaction in various cell
types activates the RAS signaling pathway axis including
MAPK1 and/or AKT1, leading to gene expression of key
regulatory proteins that promote cell cycle progression,
adhesion and tube formation [34–38]. In addition,
CCN1 binds directly to the low-density lipoprotein
(LDL) receptor proteins (LRPs) and upregulates Wnt
signaling, which activates transcription of targeted genes
[39]. Collectively, CCN1 signaling culminates in the up-
regulation of a broad spectrum of genes that modulate
cell growth and differentiation and connective tissue re-
modeling (e.g., matrix metalloproteinases (MMPs), tissue
inhibitor of metalloproteinases (TIMPs), integrins, and
VEGF) [40–42].
In the adult, genome-wide scans and association stud-
ies have established that the CYR61 gene showed the
third highest mean fold expression differences in a group
of obese men with metabolic syndrome as compared
with controls [43]. Bouchard et al. further identified up
to five polymorphisms within the CYR61 gene regulatory
region and directly linked them to the levels of plasma
LDL and HDL cholesterol in a cohort of ~700 obese in-
dividuals comprising both men and women [44]. Mean-
while, Schutze et al. further identified a CA polymorphic
repeat within the CYR61 promoter, characteristic of dis-
orders affecting bone metabolism [45]. These observa-
tions provide a genetic argument in favor of the
involvement of CYR61 gene regulation in inflammatory
disorders. In support of this hypothesis, experimental
and clinical data showed that the CYR61 gene is
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and tissue repair. Increased CCN1 levels have been
found in a number of chronic inflammatory diseases in-
cluding colitis [46], rheumatoid arthritis [47], and ath-
erosclerosis [48, 49]. Moreover, analyses of fluids and
tissue biopsies from human clinical specimens have
shown increased levels of CCN1 in several ocular vascu-
lar complications, including proliferative diabetic retin-
opathy (PDR) and active ophthalmopathy [50, 51].
Similarly, the levels of CCN1 increased in retinal blood
vessels in the early stages of diabetes and in late stages
of proliferative disorders in mouse models of diabetic
and ischemic angiopathies [52, 53]. Whether CCN1 ex-
pression under pathological conditions recapitulates bio-
logical events characteristic of earlier developmental
stages, as many fetal genes do, is unknown. Interestingly,
CCN1 expression has been found to be downregulated
during tissue involution, in avascular tissues, and under
conditions associated with vasoobliteration, which is
consistent with a potential role of this protein in vessel
formation, stabilization, and integrity [54–56]. In the
mouse model of oxygen-induced retinopathy, CCN1 en-
hanced physiological adaptation of the retinal vascula-
ture to hyperoxia and reduced pathological angiogenesis
following ischemia [57]. However, CCN1 protein is a
substrate for numerous proteases that are highly
expressed and released at sites of inflammation [58]. In
particular, vitreal fluid samples from patients with PDR
contained CCN1 fragments recognizable by specific anti-
bodies to IGFBP and vWC domains, and only a few
samples exhibited an additional product that was also
detectable by TSP1-specific antibodies [25]. The trun-
cated forms containing either the partial or complete
two-module IGFBP-vWC portion were predominantly
represented in PDR fluids along with other proangio-
genic and permeability factors such as VEGF and
MMP2. Whether and how proteolytic events affect
CCN1 function, and whether this defines new cellular
responses, is yet to be elucidated.
CCN2/CTGF
The CTGF gene encoding CCN2 maps to human
chromosome 6q23.1 [59] and to the A3-B1 region of
murine chromosome 10 (Table 1) [60]. It is located
within a commonly deleted segment of chromosome 6
(q22.1–23.2) in biopsies from patients with abdominal
aortic aneurysm (AAA) [61]. Acquired chromosomal ab-
errations associated with retrotransposon propagation at
this location predispose to sporadic AAA. In addition,
genes located in this chromosomal region have been im-
plicated in the development of systemic sclerosis and
hepatic fibrosis (HF) [62, 63]. Functional single nucleo-
tide polymorphisms (SNPs, rs6918698) implicated CCN2
as a major actor in severe HF in schistosome-infectedChinese, Sudanese, and Brazilian subjects [64]. Another
study further confirmed that one CTGF gene poly-
morphism (rs6918698; −945 G/C) is a significant risk
factor for the progression of hepatitis C-related chronic
liver diseases [65].
Although congenital diseases have, thus far, not been
mapped to genetic alterations of the CTGF gene, its ex-
pression plays an important role in normal embryonic
development. The spatial and temporal expression of
CCN2 during development is similar to that of CCN1,
with high levels present in endothelium and mural cells
of the blood vessels, heart, and skeletal tissues such as
the cartilage and maturing chondrocytes [66]. This pat-
tern of CCN2 expression during development appears to
be largely conserved in vertebrates including fish, frog,
and mouse. A loss-of-CCN2 function in zebrafish
showed developmental delays and distortion of the noto-
chord [67]. Homozygous Ctgf mutant mice were found
to have short, misaligned, and inward-bent sterna and
kinked ribs, possibly due to decreased growth plate
angiogenesis, chondrocyte migration, and matrix degrad-
ation, resulting in a visibly reduced thoracic volume
[15]. Perinatal lethality ensues as the Ctgf mutant mice
showed signs of cyanosis and difficulty to breathe, con-
tinuously gasping for air. These are the characteristics of
numerous human chondrodystrophic pulmonary hypo-
plasias that frequently prove lethal soon after birth [68].
The lungs of Ctgf mutant mice were hypoplastic and
seemingly arrested at the canalicular stage of develop-
ment, with reduced cell proliferation and increased
apoptosis [69]. Reduction in lamellar body size in type II
pneumocytes, coupled with the great reduction of avail-
able alveolar space in the mutant mouse lungs, suggests
reduced surfactant production and delayed lung
maturity.
In Ctgf knockout mice, vascular and skeletal defects
begin to emerge at later stages of development [70].
Large vessels in Ctgf-null embryos show defects in the
organization of tunica media where smooth muscle cells
appear less spindle-like, more heterogeneous in size, and
not organized into distinct layers when compared to
wild-type embryos. In addition, the microvascular endo-
thelium in Ctgf-null mice is incompletely covered by
pericytes. Loss of CCN2 leads also to diminished expres-
sion of vessel maturation markers, such as angiopoietin
1, and elevated expression of immature vasculature
markers, such as versican. Furthermore, Ctgf-deficient
mice exhibit defects in endothelial basement membrane
organization where expression of fibronectin and its as-
sociation with blood vessels is significantly decreased,
subsequently leading to discontinuous incorporation of
type IV collagen in the basement membrane of the
microvasculature. In endothelial cells, CCN2 mediates
cell adhesion, directional migration, and proliferation
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integrins α5β1 and α6β1 that are required for endothelial
basement membrane formation and vessel stabilization
in vitro [72, 73]. However, besides interacting with mul-
tiple integrins, CCN2 also modulates the activities of
several other ECM components including VEGF, TGF-
β, and Wnt signaling [19]. CCN2 has been reported
to bind VEGF-A165 at two sites through its TSP1 and
CT domains [74]. In addition, the TSP1 domain of
CCN2 binds to LRP1, which acts as a co-repressor of
the Frizzled receptor and downregulates Wnt signaling
[75, 76].
In the adult, Ctgf mRNA is expressed at high levels in
the spleen, ovary, gastrointestinal tract, prostate, heart,
and testis and at lower levels in the thymus, placenta,
lung, skeletal muscle, kidney, and pancreas [77]. No ex-
pression of CCN2 has been detected in the brain, liver,
and peripheral leucocytes. Studies of diseased tissues
from human clinical specimens and animal models
established a correlation between high levels of the
CCN2 protein and excessive accumulation and depos-
ition of ECM proteins in fibrotic tissues, suggesting a
pathogenic role for CCN2 in fibroproliferative disorders
[78]. However, transgenic models of CCN2 overproduc-
tion in a number of tissues exhibited various pheno-
types, including no fibrotic reaction, mild fibrosis, and
clear fibrotic phenotypes depending on the CCN2 levels
[79]. Specific thresholds of CCN2 levels are required to
induce cell type-specific effects. At the molecular level,
CCN2 is able to stimulate the transition of differentiated
cells such as tubular epithelial cells, endothelial cells,
and fibroblasts to activated myofibroblasts [80–82]. In
this transition, proteins that are expressed by differenti-
ated cells, such as E-cadherin in epithelial cells, are lost
while proteins expressed by myofibroblasts, such as
fibrillar collagens and α-smooth muscle actin, are
expressed [83]. There is evidence that anti-CCN2 ther-
apy can successfully attenuate fibrotic reactions in the
kidney, liver, and other organs exhibiting fibrotic reac-
tions, suggesting that therapies targeting CCN2 and its
signaling pathways may be beneficial for the treatment
of the fibrotic diseases [78].
Meanwhile, CCN2 plays an important role in vascular
diseases as well. Numerous studies have shown a close
correlation in topography and timing between CTGF
gene expression and spatial distribution and expansion
of the blood vessels in response to ischemic injury, as in
neovascular diseases of the eye [51]. Examination of the
vascular implications of CCN2 expression, or lack
thereof, in response to hyperoxic or hyperglycemic
injury showed a close correlation between CTGF gene
expression and blood vessel growth and stabilization
[51, 84, 85]. Chintala et al. have shown that CCN2
induces neovascularization through p53-dependentmodulation of MMP2 gene expression, which drives vas-
cular remodeling through degradation of the basement
membrane and subsequent formation of new vascular
patterns [86]. Interestingly, reduced levels of CCN2 in
ischemic retinas correlate with reduced VEGF gradient
levels, indicating that coordinated regulation between
CCN2 and VEGF indeed exists. CCN2 can bind VEGF
and inhibit the angiogenic activity of both molecules
when MMPs are not available, forming a negative feed-
back loop among these angiogenic factors [87].
CCN3/NOV
CCN3 is encoded by the NOV gene which maps to hu-
man chromosome 8q24.1. CCN3 is expressed during de-
velopment in derivatives of all three germ layers, with
high levels detected in skeletal muscle, smooth muscle
of vessel walls, the nervous system, adrenal cortex, and
differentiating chondrocytes [88, 89]. CCN3 seems to
play a role during myogenesis and in the formation and/
or stabilization of adhesion structures specialized in
force transmission from the muscle to tendon [90].
However, CCN3-deficient mice developed normally to
adulthood and both the males and females were fertile
[91]. Similarly, mutant mice in which the protein had
lost the vWC domain were in apparent good health
although numerous skeletal defects were observed [92].
In particular, development of the appendicular and axial
skeleton was affected with enlarged vertebrae, elongated
long bones and digits, delayed ossification, increased
bone mineralization, and severe joint malformations. In
addition, enlargement and abnormal remodeling of the
endocardial cushions, associated with septal defects and
delayed fusion, were observed in developing embryos. In
adults, cardiomyopathy was apparent, with hypertrophy
and calcification of the septum and left ventricle dilation.
Muscle atrophy was seen by 5 months of age, associated
with transdifferentiation to fat. Premature tissue de-
generation was also seen in the lens, with cataracts in
6-month-old mice.
CCN3 transgenic mice, in which CCN3 expression
was driven by a 2.3-kb Col1a1 promoter, showed
osteopenia compared with wild-type mice [93]. In
addition, bone regeneration in Nov knockout mice
was accelerated compared with that in wild-type mice.
CCN3 acts as a selective negative regulator of the ex-
pression of osteoblast-related genes, e.g., Runx2, Sp7,
Col1a1, Alpl, and Bglap, and inhibits osteoblastic dif-
ferentiation [94]. In addition, CCN3 function has been
attributed to its functional and physical interactions
with many molecules such as integrin, bone morpho-
genic proteins (BMPs), and Notch [95]. CCN3 was
proposed to fine tune the activity of BMPs during
bone regeneration by antagonizing BMP effects on its
downstream targets such as Noggin, Chordin, and
Krupska et al. Human Genomics  (2015) 9:24 Page 9 of 13Gremlin1. BMP inhibition by CCN3 results in the
suppression of mesenchymal stem cells differentiating
into osteoblasts [39]. Moreover, CCN3 binds to spe-
cific epidermal growth factor motifs of the Notch re-
ceptor and activates downstream signaling during
myogenesis, which underscores the multifaceted activ-
ities of this molecule [96].
CCN4/WISP1
CCN4 was initially published as “Wisp1” because, like
WISP2/CCN5 and WISP3/CCN6, it was induced by
WNT1 but not by WNT4 [10]. CCN4 was initially iden-
tified in the mouse mammary epithelial cell line C57MG
transformed by WNT1 [97]. EST database screening fur-
ther identified Wisp1 as homologous to Nov [98]. CCN4
expression is restricted to osteoblast and osteoblastic
progenitor cells during development and bone fracture
repair [99]. CCN4 is expressed in several adult tissues
including the epithelium, heart, kidney, lung, pancreas,
placenta, ovaries, small intestine, spleen, and brain [100].
CCN4 availability is modulated by interactions with
decorin and biglycan, two ECM-associated proteoglycans
[99]. In addition, CCN4 potentiates the effect of BMP2
on osteoprogenitor cells in the bone marrow and pro-
motes osteoblastic differentiation while repressing
chondrocytic differentiation [101, 102]. CCN4 en-
hances BMP2 signaling through a mechanism involv-
ing binding to integrin α5β1 [102]. This is unlike
other CCN proteins like CCN2 and CCN3, which ra-
ther inhibit BMP activity in osteoblastic lineage differ-
entiation [103]. CCN4 variant WISP1v lacking the
vWC module was reported in a few human gastro-
intestinal cancer tissues and normal chondrocytes
undergoing endochondrial ossification [104]. Indeed,
overexpression of WISP1v enhanced the gene expres-
sion of alkaline phosphatase, a mineralization marker
in chondrocytic cells [105].
Meanwhile, previous studies have identified WISP1 as
an oncogene that accelerates growth and morphological
transformation of alveolar epithelial cells and attenuates
cell apoptosis in response to DNA damage [106]. CCN4
signaling inhibits cell death following DNA damage by
activation of the pro-survival AKT pathway and the anti-
apoptotic BCL2L1 (Bcl-XL) [107]. Subsequently, mito-
chondrial release of the cytochrome c and caspase
cascade is suppressed. In a similar way, activation of the
AKT kinase pathway in alveolar epithelial type II (ATII)
cells treated with CCN4 induces a significant increase in
cell proliferation, epithelial-mesenchymal transition
(EMT), upregulation of gene expression of pro-fibrotic
markers, and production of ECM [108]. These effects
were confirmed in both the mouse model of pulmonary
fibrosis and patients with idiopathic pulmonary fibrosis,
which leads to distortion of normal tissue architectureand a loss of lung function [109]. Most importantly, re-
duction of CCN4 activity by CCN4-specific antibodies
resulted in decreased expression of genes characteristic
of fibrosis and significantly attenuated the progression of
the lung fibrosis suggesting that CCN4 exhibits antifi-
brotic activities opposing the profibrotic activities of
CCN2 [110].
In primary neuronal cells, CCN4 can avert microglial
inflammatory cell death during Β-amyloid (Aβ) toxicity
and prevent oxidative stress injury [111]. CCN4 promotes
neuronal cell survival during oxidative stress by enhancing
post-translational phosphorylation of FOXO3a and its se-
questration into the cytoplasm of neurons with protein
14-3-3 [112]. CCN4 also minimizes deacetylation of
FOXO3a, prevents caspase 1 and 3 activation, and poten-
tiates the neuroprotective potential of SIRT1 activity by
preventing SIRT1 caspase degradation. Therefore, CCN4
has a therapeutic potential in fibrotic and neurodegenera-
tive diseases and cancer.
CCN5/WISP2
CCN5 is structurally unique among the CCN family
members because it lacks the carboxy-terminal domain
that is responsible for the proliferative activity of CCN1
and CCN2 [17]. This suggests that CCN5 is a naturally
occurring dominant negative molecule that modulates
the effects of other CCN proteins [113].
CCN5 is expressed in nearly all embryonic stages of
development, and some level of CCN5 remains present
in multiple organs in adult organisms [114]. This wide-
spread expression pattern together with the unique
structure of CCN5 suggests that it performs a diverse
range of functions during development. CCN5 is
expressed as early as E4.5 at the implantation stage of
the blastocyst in the uterine wall and continues to be
expressed in all three germ layers: endoderm, mesoderm,
and ectoderm. It is believed that the antiproliferative ac-
tivities of CCN5 counterbalance the mitogenic activities
of the other CCN family members [114]. Not surpris-
ingly, CCN5-null mice and transgenic mice overexpress-
ing CCN5 die at or before gastrulation due to improper
implantation [115]. CCN5 is closely associated with the
cell surface, although its presence is also detected in the
nucleus in the cells of multiple adult organs including
the kidney, ovary, brain, heart, and lung [116]. Particu-
larly, high levels of CCN5 expression are found in the
endothelium and smooth muscle of the veins, arteries,
and the myocardium of the heart in early embryonic and
adult tissues. CCN5 inhibits the proliferation and migra-
tion of the smooth muscle in both cell culture and
animal models [117, 118]. Consequently, it prevents in-
vasiveness of cells by decreasing the activities of MMPs
[119]. Expression of CCN5 is highly upregulated by es-
trogen, especially in MCF-7 breast cancer lines that
Krupska et al. Human Genomics  (2015) 9:24 Page 10 of 13express estrogen receptor alpha (ESR1), making it an
oncogene [120]. WISP4 knockdown by sh-CCN5 in
MCF-7 breast cancer cells leads to an increased expres-
sion of the components of the TGFB1 (TGF-β) signaling
pathway and induction of breast cancer invasiveness.
TGFB1 plays an important role in tumor progression by
promoting angiogenesis, EMT, and metastasis [121].
CCN5 attenuates TGFB1 signaling and, by the same
token, suppresses the progression of CCN2-mediated
fibrogenesis [122]. Concordantly, TGFB1 signaling and
cardiac fibrosis are inhibited in CCN5 transgenic mice in
contrast to CCN2 transgenic mice. A study by Yoon et al.
further demonstrated that deletion of the C-terminal
domain of CCN2 transformed CCN2 into a CCN5-like
molecule, whereas fusion of the CT domain of CCN2 to
the carboxy-terminus of CCN5 transformed CCN5 into a
CCN2-like pro-hypertrophic and pro-fibrotic molecule in
cardiomyocytes [122].
CCN6/WISP3
CCN6 is an essential protein involved in the mainten-
ance of human articular cartilage [123]. Mutations in
human WISP3 cause progressive pseudorheumatoid
dysplasia that manifests itself in early childhood with
loss of articular cartilage causing multiple joint and
bone abnormalities [124]. Surprisingly, no apparent
phenotype was caused by CCN6 deficiency in mice,
which made it challenging to understand the func-
tional significance of CCN6 in development and dis-
ease. Importantly, CCN6 seems to be involved in
gene regulation of proteinases, such as the ADAMTSs
and MMPs that cause cartilage matrix degradation
found in PPD [123, 125]. Overexpression of CCN6 in
immortalized chondrocytic cell lines dramatically re-
duced the expression of ADAMTS4 and ADAMTS5,
while the expression of MMP1 and MMP10 was ele-
vated [123]. On the other hand, WISP3 knockdown in
cytokine-stimulated primary chondrocytes resulted in
elevated expression of ADAMTS5 and repression of
MMP10. These observations suggest that CCN6 is
involved in complex context-dependent control of
metalloproteinase expression. However, CCN6 was
shown to be downregulated in invasive and metastatic
breast cancers, suggesting that it also exerts a tumor
suppressive function [126]. In the absence of CCN6,
there is activation of the BMP4-induced SMAD-
independent MAP3K7 (TAK1)/MAPK14 (p38) path-
way that promotes invasion [127]. Conversely, when
present, CCN6 protein binds to BMP4 and inhibits
the BMP4-mediated activation of MAP3K7/MAPK14
kinases and decreases the invasiveness of breast can-
cer cells [128]. Thus, CCN6 can be considered as a
possible therapeutic target for breast and metastatic
cancers.Conclusion
Taken together, data shows that the CCN proteins regu-
late development and pathology of different organ systems
in various contexts. The requirement of CCN1, CCN2,
and CCN5 for embryonic viability indicates their import-
ance in tissue formation, organization, and function. Sur-
vival of mice deficient in CCN3, CCN4, or CCN6 suggests
that either these molecules are not required for structural
integrity and/or function or the existence of a functional
redundancy with other molecules. However, all CCN pro-
teins seem to be involved in the physiological and/or
pathological responses of tissues and organ systems to in-
jurious stimuli. Whether re-expression of these proteins in
disease states recapitulates developmental processes is still
unknown. Clearly, the function of all CCN proteins are
cell- and tissue-specific and careful consideration of the
context in which they are expressed should be taken into
consideration when assessing their usefulness as potential
markers or therapeutic targets in pathological conditions.
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